TRVI — Trevi Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1563880 ·
Last close
$13.51
Market Cap
$1.93B
52W High
$20.22
52W Low
$9.82
ADV30
2,211,372
Next earnings
2026-11-09
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -24,486,000 -21,452,000 310,812,000 27,849,000 8,056,000
Jun 2026 0 — -20,509,000 -17,797,000 330,518,000 54,302,000 9,012,000
Mar 2026 0 — -14,912,000 -13,192,000 179,606,000 19,412,000 7,479,000
Dec 2025 0 — -10,220,000 -8,316,000 193,439,000 18,914,000 10,195,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-61,436,000
Investing CF
$-132,859,000
Financing CF
$165,275,000
CapEx
$-251,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.39
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-382,245,000
Inventory
—
Receivables
—
ST Investments
$271,559,000
EBIT TTM
$-68,239,000
Pretax Income TTM
$-60,831,000
Interest Exp TTM
$0
Analysts
11

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -49,328,000 -42,759,000 193,439,000 10,195,000 183,244,000 -42,089,000
Dec 2024 0 -51,524,000 -47,911,000 110,900,000 11,256,000 99,644,000 -38,256,000
Dec 2023 0 -33,923,000 -29,065,000 89,403,000 6,856,000 82,547,000 -31,710,000
Dec 2022 0 -29,907,000 -29,152,000 123,015,000 15,556,000 107,459,000 -28,175,000

TTM Snapshot

Revenues TTM
$8,396,000
NetIncome TTM
$-51,107,000
OpCashFlow TTM
—
Assets (Latest)
$330,518,000
Forward EPS
$-0.60

Max Pain — expiry 2027-01-15

max pain strike: $7.00 · spot: $13.51 · call oi: 9,502 · put oi: 384
Expected Move to 2027-01-15: ±$2.88 (21.28%) — implied range $10.63 – $16.38 · ATM straddle on $14.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
HRMY Harmony Biosciences Holdings, Inc. $1.94B $33.01 —
SEPN Septerna, Inc. $1.90B $40.02 —
VERA Vera Therapeutics, Inc. $1.89B $26.20 —
ZBIO Zenas BioPharma, Inc. $1.88B $27.75 —
HMDCF HUTCHMED (China) Ltd $1.88B $2.16 —

News headlines (Yahoo Finance, 1h cache)

Does Wider Losses Change The Bull Case For Trevi Therapeutics Stock (TRVI)?
2026-11-10 20:09 · Yahoo
Trevi Therapeutics, Inc. Q3 2026 Earnings Call Summary
2026-11-10 13:30 · Yahoo
Trevi Therapeutics Inc (TRVI) Q3 2026 Earnings Call Highlights: Strong Cash Position, FDA ...
2026-11-10 07:09 · Yahoo
Trevi Therapeutics (TRVI) Q3 2026 Earnings Call Transcript
2026-11-10 06:47 · Yahoo
What Trevi Therapeutics (TRVI) Said on Its Q3 Earnings Call
2026-11-09 23:14 · Yahoo
Trevi Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates
2026-11-09 21:05 · Yahoo
Trevi Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 9, 2026
2026-11-02 21:05 · Yahoo
Trevi Therapeutics (TRVI) Stock May Still Look Expensive Against Book Value
2026-11-01 16:05 · Yahoo
Trevi Therapeutics to Participate in Stifel's 2026 Healthcare Conference
2026-10-27 11:30 · Yahoo
Do Trevi Therapeutics’ (TRVI) CORAL Data and GSK’s Exit Reframe Its Chronic Cough Ambitions?
2026-10-13 22:14 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.